Incretin analog-containing compositions and uses thereof
AssigneeEli Lilly and Company
InventorsGanapathy Gopalrathnam, Christopher Sears Minie
Life of this patent
Estimating the term…
Abstract
A composition is provided that includes an incretin analog having activity at each the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors (i.e., tri-receptor agonist) and one or more additional agents such as a tonicity agent and a preservative. Methods also are provided for treating diseases such as type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and obesity with the composition.
Claims41
A pharmaceutical composition comprising:
- an incretin analog comprising SEQ ID NO:1, or pharmaceutically acceptable salt thereof;
- a tris(hydroxymethyl)aminomethane (TRIS) buffer;
- at least one tonicity agent selected from the group consisting of glycerin, mannitol and propylene glycol;
- and
- an optional preservative selected from the group consisting of m-cresol and phenol.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.